Stephen Hanlon, MD
Cardiovascular Disease · Manchester, NHNPI 1972683092
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,195 of the $2,523 with a category attached, or 87.0%. 12 manufacturers reported payments, led by Abbott at 45.4% of the total. Reporting peaked in 2019 at $702 and has fallen 62.5% since, to $264 in 2025.
Across 44 payments — averaging $57.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Boston Scientific$343
- AstraZeneca$164
- Pfizer$152
- Heartflow, Inc.$149
- Abiomed$149
- plus $421 from 6 others
Across 7 payments — averaging $4201.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Impulse Dynamics (USA) Inc.$29K
What the payments were for
- Travel & lodging$31412%
- Food & beverage$2,19587%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 22 | $1,146 |
| Boston Scientific | 5 | $343 |
| AstraZeneca | 3 | $164 |
| Pfizer | 2 | $152 |
| Heartflow, Inc. | 1 | $149 |
| Abiomed | 1 | $149 |
| Impulse Dynamics (USA) Inc. | 1 | $144 |
| Boehringer Ingelheim | 1 | $115 |
| Amarin Pharma, Inc. | 5 | $91 |
| Johnson & Johnson | 1 | $24 |
| Philips North America LLC | 1 | $24 |
| Lantheus Medical Imaging, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$287
- CARDIOMEMS$255
- Tendyne Mitral Valve System$158
- FFRct$149
- Impella$149
- GENERAL - STRUCTURAL HEART$101
How this compares
$2,523 in reported general payments places this provider in the 70th percentile of 112 cardiovascular disease providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 192 | $227,767 |
| FarxigaDapagliflozin Propanediol | 112 | $110,942 |
| EntrestoSacubitril/Valsartan | 88 | $94,709 |
| JardianceEmpagliflozin | 77 | $69,412 |
| XareltoRivaroxaban | 31 | $45,722 |
| BrilintaTicagrelor | 15 | $7,728 |
| Torsemide | 152 | $7,517 |
| Metoprolol Succinate | 307 | $4,288 |
| Potassium Chloride | 93 | $3,496 |
| Dofetilide | 11 | $2,914 |
| Amiodarone Hcl | 86 | $1,956 |
| Rosuvastatin Calcium | 95 | $1,830 |
| Valsartan | 72 | $1,829 |
| Atorvastatin Calcium | 177 | $1,747 |
| Ranolazine ErRanolazine | 21 | $1,490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $152 | $227,767192 claims |
| AstraZenecaFarxiga, Brilinta | $164 | $118,669127 claims |
| Boehringer IngelheimJardiance | $115 | $69,41277 claims |
| Johnson & JohnsonXarelto | $24 | $45,72231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 112 cardiovascular disease providers in New Hampshire.
Other cardiovascular disease in Manchester
- Fahad GilaniManchester$418K
- Stephan HeoManchester$116K
- Robert CapodilupoManchester$85K
- Jeanney LewManchester$36K
- Jinu JohnManchester$12K
- Michelle OuelletteManchester$7K
- Patrick HickleManchester$5K
- Jeffrey BleakleyManchester$5K
- Tong ZhuManchester$4K
- Alan GarstkaManchester$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.